Latest News
Nurix Therapeutics, Inc.
- Nurix Therapeutics CSO Gwenn Hansen sells $36,300 in common stock
- Nurix Therapeutics Director Sold Shares Worth Over $528K
- Nurix Therapeutics reports Q3 2026 revenue $673.1M, net income $549.8M and $1.1B cash
- Nurix Therapeutics Q3FY26 Results: EPS $4.73 beats estimate, revenue $673.1M
- Nurix Therapeutics Fiscal Q3 Swings to Profit, Revenue Rises; Shares Gain After Hours
- BTK degrader clinical program progresses as Nurix Therapeutics delivers Q3 2026 results
- Nurix Therapeutics Q3 swings to profit on Roche collaboration
- Nurix Therapeutics earnings in spotlight amid pipeline gains By Investing.com
- Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia
- Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences
Headlines from the last 30 days, linking to the original publishers. See all market news →